Suicidality
Conditions
Brief summary
Anecdotal evidence and several clinical studies found the mixed opioid agonist-antagonist Nopan to be an effective antidepressant with a rapid onset of action. It is therefore hypothesized that Nopan may be a novel and quick-acting treatment for acute suicidality. Depression, suicidality, and overall functioning will be assessed before, during and after a four-week Nopan/placebo trial. It is hypothesized that subjects who receive the active drug will show rapid improvements in objective and subjective measures of these variables.
Interventions
DRUGNopan
Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
DRUGPlacebo
Placebo in a manner similar to the active comparator
Sponsors
University of Haifa
Prof. Yoram Yovell
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* suicidal behavior or ideation (BSI\>6)
Exclusion criteria
* ECT history within the last month * psychotic features within the last 3 months * history of schizophrenia, substance or alcohol abuse within the last two years * benzodiazepine dependence within the last two years * any significant systemic illness or unstable medical condition which does not permit inclusion, according to the research physician * pregnant women * patients who currently suffer from severe impairment or severe dysfunction of liver, kidney, adrenal, gall, closed brain injury, urinary retention or respiratory system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Suicidality as expressed by the score on the BSI | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in depression as measured by the BDI | 4 weeks |
Countries
Israel
Contacts
Primary ContactYoram Yovell, MD, PhD
Outcome results
None listed